mTORC1 / 4EBP1 Interceptor

About Apertor Pharmaceuticals

Apertor Pharmaceuticals is a private, preclinical-stage biotech pioneering a novel approach to disrupt protein-protein interactions (PPIs) in oncology. Its core technology platform develops 'Interceptors,' heterobifunctional small molecules that recruit the abundant intracellular protein FKBP12 to sterically obstruct oncogenic signaling complexes, offering a differentiated mechanism from protein degraders like PROTACs. The company is advancing a pipeline led by a program targeting mTORC1/4E-BP1 in solid tumors and is backed by a team of experienced founders and scientific advisors with deep expertise in chemical biology and drug discovery.

Therapeutic Areas